A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

Roche has secured approval from the European Commission (EC) for Columvi (glofitamab) plus gemcitabine and oxaliplatin (GemOx ...

A regimen based on Roche's CD20xCD3 bispecific antibody Columvi has been approved in the EU as a second-line therapy for ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Australian patients with the most common form of lymphoma will for the first time have access to affordable, at-home treatment options after the federal subsidisation of an injectable immunotherapy.

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.